journal
MENU ▼
Read by QxMD icon Read
search

Alzheimer's & Dementia: the Journal of the Alzheimer's Association

journal
https://read.qxmd.com/read/31101517/comparison-of-18-f-florbetaben-quantification-results-using-the-standard-centiloid-mr-based-and-mr-less-capaibl-%C3%A2-approaches-validation-against-histopathology
#1
Vincent Doré, Santiago Bullich, Christopher C Rowe, Pierrick Bourgeat, Salamata Konate, Osama Sabri, Andrew W Stephens, Henryk Barthel, Jurgen Fripp, Colin L Masters, Ludger Dinkelborg, Olivier Salvado, Victor L Villemagne, Susan De Santi
INTRODUCTION: 18 F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. METHODS: Data from eighty-eight subjects (52 male subjects, aged 79.8 ± 10.6 years) who underwent antemortem 18 F-florbetaben positron emission tomography scan and magnetic resonance imaging less than a year before neuropathological assessment at autopsy were evaluated...
May 14, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31088775/assessment-of-executive-function-declines-in-presymptomatic-and-mildly-symptomatic-familial-frontotemporal-dementia-nih-examiner-as-a-potential-clinical-trial-endpoint
#2
Adam M Staffaroni, Lynn Bajorek, Kaitlin B Casaletto, Yann Cobigo, Sheng-Yang M Goh, Amy Wolf, Hilary W Heuer, Fanny M Elahi, Peter A Ljubenkov, Reilly Dever, John Kornak, Brian Appleby, Jessica Bove, Yvette Bordelon, Patrick Brannelly, Danielle Brushaber, Christina Caso, Giovanni Coppola, Christina Dheel, Bradford C Dickerson, Susan Dickinson, Sophia Dominguez, Kimiko Domoto-Reilly, Kelly Faber, Jessica Ferrall, Julie A Fields, Ann Fishman, Jamie Fong, Tatiana Foroud, Leah K Forsberg, Ralitza Gavrilova, Debra Gearhart, Behnaz Ghazanfari, Nupur Ghoshal, Jill Goldman, Jonathan Graff-Radford, Neill Graff-Radford, Ian Grant, Murray Grossman, Dana Haley, Ging-Yuek Hsiung, Edward D Huey, David J Irwin, David T Jones, Lynne Jones, Kejal Kantarci, Anna Karydas, Daniel I Kaufer, Diana R Kerwin, David S Knopman, Ruth Kraft, Walter K Kremers, Walter A Kukull, Irene Litvan, Diane Lucente, Codrin Lungu, Ian R Mackenzie, Miranda Maldonado, Masood Manoochehri, Scott M McGinnis, Emily McKinley, Mario F Mendez, Bruce L Miller, Namita Multani, Chiadi Onyike, Jaya Padmanabhan, Alex Pantelyat, Rodney Pearlman, Len Petrucelli, Madeline Potter, Rosa Rademakers, Eliana Marisa Ramos, Katherine P Rankin, Katya Rascovsky, Erik D Roberson, Emily Rogalski, Pheth Sengdy, Leslie M Shaw, Jeremy Syrjanen, M Carmela Tartaglia, Nadine Tatton, Joanne Taylor, Arthur Toga, John Q Trojanowski, Sandra Weintraub, Ping Wang, Bonnie Wong, Zbigniew Wszolek, Adam L Boxer, Brad F Boeve, Joel H Kramer, Howard J Rosen
INTRODUCTION: Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression. METHODS: Ninety-three mutation carriers with no symptoms or minimal/questionable symptoms (MAPT, n = 31; GRN, n = 28; C9orf72, n = 34; Clinical Dementia Rating scale plus NACC FTLD Module < 1) and 78 noncarriers enrolled through Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects studies completed the Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH-EXAMINER) and the UDS neuropsychological battery...
May 11, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31076376/the-mopead-project-advancing-patient-engagement-for-the-detection-of-hidden-undiagnosed-cases-of-alzheimer-s-disease-in-the-community
#3
REVIEW
Octavio Rodríguez-Gómez, Adrián Rodrigo, Fátima Iradier, Miguel A Santos-Santos, Hans Hundemer, Andreea Ciudin, Lena Sannemann, Marissa Zwan, Bridget Glaysher, Anders Wimo, Jaka Bonn, Gunilla Johansson, Isabel Rodriguez, Montse Alegret, Dianne Gove, Susana Pinó, Paloma Trigueros, Miia Kivipelto, Brandy Mathews, Antonio Ciudad, Daniel Ferreira, Christophe Bintener, Miren Gurruchaga, Eric Westman, Mark Belger, Sergi Valero, Peggy Maguire, David Krivec, Milica Kramberger, Rafael Simó, Inmaculada Pérez Garro, Pieter Jelle Visser, Annette Dumas, Jean Georges, Frank Jessen, Bengt Winblad, Craig Shering, Neil Stewart, Laura Campo, Mercè Boada
In most, if not all health systems, dementia is underdiagnosed, and when diagnosis occurs, it is typically at a relatively late stage in the disease process despite mounting evidence showing that a timely diagnosis would result in numerous benefits for patients, families, and society. Moving toward earlier diagnoses in Alzheimer's disease (AD) requires a conscientious and collective effort to implement a global strategy addressing the multiple causes hindering patient engagement at different levels of society...
May 6, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31064709/erratum-to-kallikrein-8-inhibition-attenuates-alzheimer-s-disease-pathology-in-mice-alzheimer-s-dementia-2016-12-1273-87
#4
(no author information available yet)
No abstract text is available yet for this article.
May 4, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31056344/brain-atrophy-in-primary-age-related-tauopathy-is-linked-to-transactive-response-dna-binding-protein-of-43-kda
#5
Keith A Josephs, Melissa E Murray, Nirubol Tosakulwong, Stephen D Weigand, David S Knopman, Ronald C Petersen, Clifford R Jack, Jennifer L Whitwell, Dennis W Dickson
INTRODUCTION: Primary age-related tauopathy (PART) is characterized by the presence of neurofibrillary tangles and absent-minimal β-amyloid deposition. Transactive response DNA-binding protein of 43 kDa (TDP-43), a third protein, has recently garnished a lot of attention in Alzheimer's disease where it is associated with memory loss and amygdala and hippocampal atrophy. We aimed to determine whether TDP-43 is associated with brain atrophy in PART. METHODS: We assessed the frequency of TDP-43 in PART and performed voxel-level analysis in SPM12, as well as region-of-interest analysis using linear regression modeling, controlling for variables of interest, to assess for associations between TDP-43 and brain atrophy...
May 2, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31056343/urate-and-risk-of-alzheimer-s-disease-and-vascular-dementia-a-population-based-study
#6
Lieke E J M Scheepers, Lennart T H Jacobsson, Silke Kern, Lena Johansson, Mats Dehlin, Ingmar Skoog
INTRODUCTION: Low serum urate (sU) has been suggested to increase the risk of dementia since a reduction might impair antioxidant capacity. On the other hand, high sU is associated with increased cardiovascular risk which might increase the risk of dementia, especially for vascular dementia. METHODS: In 1968-1969, a population-based sample of 1462 women aged 38 to 60 years was examined and were followed up over 44 years (mean 33.1 years). We examined whether sU (determined in 1968-1969 and 1992-1994) is associated with risk of late-life dementia...
May 2, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31047857/adherence-to-multidomain-interventions-for-dementia-prevention-data-from-the-finger-and-mapt-trials
#7
Nicola Coley, Tiia Ngandu, Jenni Lehtisalo, Hilkka Soininen, Bruno Vellas, Edo Richard, Miia Kivipelto, Sandrine Andrieu
INTRODUCTION: Multidomain interventions, targeting multiple risk factors simultaneously, could be effective dementia prevention strategies, but may be burdensome and not universally acceptable. METHODS: We studied adherence rates and predictors in the Finnish Geriatric Intervevntion Study to Prevent Cognitive Impairment and Disability and Multidomain Alzheimer Preventive Trial prevention trials, for all intervention components (separately and simultaneously). Finnish Geriatric Intervevntion Study to Prevent Cognitive Impairment and Disability participants received a 2-year multidomain lifestyle intervention (physical training, cognitive training, nutritional counseling, and cardiovascular monitoring)...
April 29, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31047856/inflammatory-biomarkers-in-alzheimer-s-disease-plasma
#8
Angharad R Morgan, Samuel Touchard, Claire Leckey, Caroline O'Hagan, Alejo J Nevado-Holgado, Frederik Barkhof, Lars Bertram, Olivier Blin, Isabelle Bos, Valerija Dobricic, Sebastiaan Engelborghs, Giovanni Frisoni, Lutz Frölich, Silvey Gabel, Peter Johannsen, Petronella Kettunen, Iwona Kłoszewska, Cristina Legido-Quigley, Alberto Lleó, Pablo Martinez-Lage, Patrizia Mecocci, Karen Meersmans, José Luis Molinuevo, Gwendoline Peyratout, Julius Popp, Jill Richardson, Isabel Sala, Philip Scheltens, Johannes Streffer, Hikka Soininen, Mikel Tainta-Cuezva, Charlotte Teunissen, Magda Tsolaki, Rik Vandenberghe, Pieter Jelle Visser, Stephanie Vos, Lars-Olof Wahlund, Anders Wallin, Sarah Westwood, Henrik Zetterberg, Simon Lovestone, B Paul Morgan
INTRODUCTION: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. METHODS: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed...
April 29, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31078433/primary-fatty-amides-in-plasma-associated-with-brain-amyloid-burden-hippocampal-volume-and-memory-in-the-european-medical-information-framework-for-alzheimer-s-disease-biomarker-discovery-cohort
#9
Min Kim, Stuart Snowden, Tommi Suvitaival, Ashfaq Ali, David J Merkler, Tahmina Ahmad, Sarah Westwood, Alison Baird, Petroula Proitsi, Alejo Nevado-Holgado, Abdul Hye, Isabelle Bos, Stephanie Vos, Rik Vandenberghe, Charlotte Teunissen, Mara Ten Kate, Philip Scheltens, Silvy Gabel, Karen Meersmans, Olivier Blin, Jill Richardson, Ellen De Roeck, Kristel Sleegers, Régis Bordet, Lorena Rami, Petronella Kettunen, Magda Tsolaki, Frans Verhey, Isabel Sala, Alberto Lléo, Gwendoline Peyratout, Mikel Tainta, Peter Johannsen, Yvonne Freund-Levi, Lutz Frölich, Valerija Dobricic, Sebastiaan Engelborghs, Giovanni B Frisoni, José L Molinuevo, Anders Wallin, Julius Popp, Pablo Martinez-Lage, Lars Bertram, Frederik Barkhof, Nicholas Ashton, Kaj Blennow, Henrik Zetterberg, Johannes Streffer, Pieter J Visser, Simon Lovestone, Cristina Legido-Quigley
INTRODUCTION: A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. METHODS: This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115)...
April 28, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31031101/quantifying-blood-brain-barrier-leakage-in-small-vessel-disease-review-and-consensus-recommendations
#10
REVIEW
Michael J Thrippleton, Walter H Backes, Steven Sourbron, Michael Ingrisch, Matthias J P van Osch, Martin Dichgans, Franz Fazekas, Stefan Ropele, Richard Frayne, Robert J van Oostenbrugge, Eric E Smith, Joanna M Wardlaw
Cerebral small vessel disease (cSVD) comprises pathological processes of the small vessels in the brain that may manifest clinically as stroke, cognitive impairment, dementia, or gait disturbance. It is generally accepted that endothelial dysfunction, including blood-brain barrier (BBB) failure, is pivotal in the pathophysiology. Recent years have seen increasing use of imaging, primarily dynamic contrast-enhanced magnetic resonance imaging, to assess BBB leakage, but there is considerable variability in the approaches and findings reported in the literature...
April 25, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31031100/mitigating-stigma-of-alzheimer-s-disease-dementia-among-chinese-americans
#11
LETTER
Benjamin K P Woo, Siubak Chung, Gina Woo, Jamie O P Chung
No abstract text is available yet for this article.
April 25, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/31010788/aaron-klug-and-the-study-of-alzheimer-s-disease
#12
Michel Goedert
No abstract text is available yet for this article.
April 19, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/30979540/dementia-paradigm-shifting-into-high-gear
#13
REVIEW
Vladimir Hachinski
Redressing the rising threat of dementia demands not only an increase, but a diversification of efforts. We need new approaches, trials, and partners. We cannot afford to continue to only round up the usual suspects, β amyloid, and tau and try to stop them with a single drug "silver bullet". Dementia of late onset is not a disease, but an amalgam of interactive pathologies on the shifting background of aging, requiring multimodal targeting. Cerebrovascular diseases coexist and coact with all major neurodegenerative pathologies, increasing two-fold the likelihood that they will manifest clinically...
April 9, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/30967340/longitudinal-cerebrospinal-fluid-biomarker-trajectories-along-the-alzheimer-s-disease-continuum-in-the-biomarkapd-study
#14
Alberto Lleó, Daniel Alcolea, Pablo Martínez-Lage, Philip Scheltens, Lucilla Parnetti, Judes Poirier, Anja H Simonsen, Marcel M Verbeek, Pedro Rosa-Neto, Rosalinde E R Slot, Mikel Tainta, Andrea Izaguirre, Babette L R Reijs, Lucia Farotti, Magda Tsolaki, Rik Vandenbergue, Yvonne Freund-Levi, Frans R J Verhey, Jordi Clarimón, Juan Fortea, Lutz Frolich, Isabel Santana, José Luis Molinuevo, Sylvain Lehmann, Pieter J Visser, Charlotte E Teunissen, Henrik Zetterberg, Kaj Blennow
INTRODUCTION: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. METHODS: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL)...
April 6, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/30935898/novel-methods-for-integration-and-visualization-of-genomics-and-genetics-data-in-alzheimer-s-disease
#15
Nathan A Bihlmeyer, Emily Merrill, Yann Lambert, Gyan P Srivastava, Timothy W Clark, Bradley T Hyman, Sudeshna Das
INTRODUCTION: Numerous omics studies have been conducted to understand the molecular networks involved in Alzheimer's disease (AD), but the pathophysiology is still not completely understood; new approaches that enable neuroscientists to better interpret the results of omics analysis are required. METHODS: We have developed advanced methods to analyze and visualize publicly-available genomics and genetics data. The tools include a composite clinical-neuropathological score for defining AD, gene expression maps in the brain, and networks integrating omics data to understand the impact of polymorphisms on AD pathways...
March 29, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/30905591/erratum-to-altered-bile-acid-profile-associates-with-cognitive-impairment-in-alzheimer-s-disease-an-emerging-role-for-gut-microbiome-alzheimer-s-dementia-2019-15-76-92
#16
(no author information available yet)
No abstract text is available yet for this article.
March 21, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/30894299/the-effects-of-7-week-cognitive-training-in-patients-with-vascular-cognitive-impairment-no-dementia-the-cog-vaccine-study-a-randomized-controlled-trial
#17
Yi Tang, Yi Xing, Zude Zhu, Yong He, Fang Li, Jianwei Yang, Qing Liu, Fangyu Li, Stefan J Teipel, Guoguang Zhao, Jianping Jia
INTRODUCTION: Evidence for the efficacy of cognitive training in patients with subcortical vascular cognitive impairment no dementia is still lacking. METHODS: A randomized, active controlled design using multidomain, adaptive, computerized cognitive training for 30 minutes, 5 days/week for 7 weeks. Assessments included global cognitive function and executive function (primary outcomes) and brain functional connectivity and structural changes (secondary outcomes)...
March 17, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/30872115/impact-of-helicobacter-pylori-and-or-helicobacter-pylori-related-metabolic-syndrome-on-incidence-of-all-cause-and-alzheimer-s-dementia
#18
LETTER
Jannis Kountouras, Michael Doulberis, Stergios A Polyzos, Taxiarchis Katsinelos, Elizabeth Vardaka, Constantinos Kountouras, Stergios Arapoglou, Aristomenis K Exadaktylos, Georgia Deretzi, Magda Tsolaki, Marina Boziki, Panagiotis Katsinelos
No abstract text is available yet for this article.
March 11, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/30872114/a-randomized-clinical-trial-to-evaluate-home-based-assessment-of-people-over-75-years-old
#19
Mary Sano, Carolyn W Zhu, Jeffrey Kaye, James C Mundt, Tamara L Hayes, Steven Ferris, Ronald G Thomas, Chung-Kai Sun, Yanxin Jiang, Michael C Donohue, Lon S Schneider, Susan Egelko, Paul S Aisen, Howard H Feldman
INTRODUCTION: There is an unmet need for effective methods for conducting dementia prevention trials. METHODS: Home-based assessment study compared feasibility and efficiency, ability to capture change over time using in-home instruments, and ability to predict cognitive conversion using predefined triggers in a randomized clinical trial in (1) mail-in questionnaire/live telephone interviews, (2) automated telephone/interactive voice recognition, and (3) internet-based computer Kiosk technologies...
March 11, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://read.qxmd.com/read/30853466/detecting-both-current-and-prior-helicobacter-pylori-infection-is-important-to-assess-its-impact-on-dementia
#20
LETTER
Claire Roubaud-Baudron, Francis Mégraud, Nathalie Salles, Jean-François Dartigues, Luc Letenneur
No abstract text is available yet for this article.
March 7, 2019: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
journal
journal
40839
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"